Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2007 1
2010 1
2011 2
2012 3
2013 6
2014 6
2015 5
2016 10
2017 8
2018 9
2019 9
2020 8
2021 11
2022 11
2023 5
2024 5
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

87 results

Results by year

Filters applied: . Clear all
Page 1
B cells in the pathophysiology of myasthenia gravis.
Yi JS, Guptill JT, Stathopoulos P, Nowak RJ, O'Connor KC. Yi JS, et al. Among authors: guptill jt. Muscle Nerve. 2018 Feb;57(2):172-184. doi: 10.1002/mus.25973. Epub 2017 Sep 30. Muscle Nerve. 2018. PMID: 28940642 Free PMC article. Review.
Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial.
Allen JA, Lin J, Basta I, Dysgaard T, Eggers C, Guptill JT, Gwathmey KG, Hewamadduma C, Hofman E, Hussain YM, Kuwabara S, Le Masson G, Leypoldt F, Chang T, Lipowska M, Lowe M, Lauria G, Querol L, Simu MA, Suresh N, Tse A, Ulrichts P, Van Hoorick B, Yamasaki R, Lewis RA, van Doorn PA; ADHERE Study Group. Allen JA, et al. Among authors: guptill jt. Lancet Neurol. 2024 Oct;23(10):1013-1024. doi: 10.1016/S1474-4422(24)00309-0. Lancet Neurol. 2024. PMID: 39304241 Clinical Trial.
Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors.
Guidon AC, Burton LB, Chwalisz BK, Hillis J, Schaller TH, Amato AA, Betof Warner A, Brastianos PK, Cho TA, Clardy SL, Cohen JV, Dietrich J, Dougan M, Doughty CT, Dubey D, Gelfand JM, Guptill JT, Johnson DB, Juel VC, Kadish R, Kolb N, LeBoeuf NR, Linnoila J, Mammen AL, Martinez-Lage M, Mooradian MJ, Naidoo J, Neilan TG, Reardon DA, Rubin KM, Santomasso BD, Sullivan RJ, Wang N, Woodman K, Zubiri L, Louv WC, Reynolds KL. Guidon AC, et al. Among authors: guptill jt. J Immunother Cancer. 2021 Jul;9(7):e002890. doi: 10.1136/jitc-2021-002890. J Immunother Cancer. 2021. PMID: 34281989 Free PMC article.
Safety profile of efgartigimod from global clinical trials across multiple immunoglobulin G-mediated autoimmune diseases.
Gwathmey KG, Broome CM, Goebeler M, Murai H, Bata-Csörgo Z, Newland AC, Allen JA, Miyakawa Y, Ulrichts P, Truyen L, Podhorna J, Kerstens R, Steeland S, Beauchamp J, Guptill JT, Howard JF Jr. Gwathmey KG, et al. Among authors: guptill jt. Expert Rev Clin Immunol. 2025 May;21(5):627-638. doi: 10.1080/1744666X.2025.2497840. Epub 2025 May 13. Expert Rev Clin Immunol. 2025. PMID: 40296516 Free article. Clinical Trial.
Randomized phase 2 study of ACE-083, a muscle-promoting agent, in facioscapulohumeral muscular dystrophy.
Statland JM, Campbell C, Desai U, Karam C, Díaz-Manera J, Guptill JT, Korngut L, Genge A, Tawil RN, Elman L, Joyce NC, Wagner KR, Manousakis G, Amato AA, Butterfield RJ, Shieh PB, Wicklund M, Gamez J, Bodkin C, Pestronk A, Weihl CC, Vilchez-Padilla JJ, Johnson NE, Mathews KD, Miller B, Leneus A, Fowler M, van de Rijn M, Attie KM. Statland JM, et al. Among authors: guptill jt. Muscle Nerve. 2022 Jul;66(1):50-62. doi: 10.1002/mus.27558. Epub 2022 May 9. Muscle Nerve. 2022. PMID: 35428982 Free PMC article. Clinical Trial.
A Phase 1 Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of (2R,6R)-Hydroxynorketamine in Healthy Volunteers.
Raja SM, Guptill JT, Mack M, Peterson M, Byard S, Twieg R, Jordan L, Rich N, Castledine R, Bourne S, Wilmshurst M, Oxendine S, Avula SGC, Zuleta H, Quigley P, Lawson S, McQuaker SJ, Ahmadkhaniha R, Appelbaum LG, Kowalski K, Barksdale CT, Gufford BT, Awan A, Sancho AR, Moore MC, Berrada K, Cogan GB, DeLaRosa J, Radcliffe J, Pao M, Kennedy M, Lawrence Q, Goldfeder L, Amanfo L, Zanos P, Gilbert JR, Morris PJ, Moaddel R, Gould TD, Zarate CA Jr, Thomas CJ. Raja SM, et al. Among authors: guptill jt. Clin Pharmacol Ther. 2024 Nov;116(5):1314-1324. doi: 10.1002/cpt.3391. Epub 2024 Jul 25. Clin Pharmacol Ther. 2024. PMID: 39054770 Free PMC article. Clinical Trial.
Advances in autoimmune myasthenia gravis management.
Wang S, Breskovska I, Gandhy S, Punga AR, Guptill JT, Kaminski HJ. Wang S, et al. Among authors: guptill jt. Expert Rev Neurother. 2018 Jul;18(7):573-588. doi: 10.1080/14737175.2018.1491310. Epub 2018 Jul 4. Expert Rev Neurother. 2018. PMID: 29932785 Free PMC article. Review.
Pharmacokinetics of Ceftazidime-Avibactam in Combination with Aztreonam (COMBINE) in a Phase 1, Open-Label Study of Healthy Adults.
Lodise TP, O'Donnell JN, Balevic S, Liu X, Gu K, George J, Raja S, Guptill JT, Zaharoff S, Schwager N, Fowler VG Jr, Wall A, Wiegand K, Chambers HF; Antibacterial Resistance Leadership Group. Lodise TP, et al. Among authors: guptill jt. Antimicrob Agents Chemother. 2022 Dec 20;66(12):e0093622. doi: 10.1128/aac.00936-22. Epub 2022 Nov 17. Antimicrob Agents Chemother. 2022. PMID: 36394326 Free PMC article. Clinical Trial.
87 results